User login
Physician-researcher who promoted industry collaboration dies unexpectedly
Thomas Peter Stossel, MD, a physician-researcher known for his discovery of cellular proteins and advocacy for academic-industry relationships, died unexpectedly on Sept. 29 at the age of 78.
Dr. Stossel’s research was largely focused on cell motility. He is known for discovering the cellular proteins filamin and gelsolin, which regulate the assembly of actin. Dr. Stossel is also known for promoting relationships between physicians and industry. He believed these relationships accelerate medical innovation.
Dr. Stossel graduated from Princeton University and Harvard Medical School. He served as chief of the hematology-oncology unit at Massachusetts General Hospital, head of experimental medicine and codirector of the hematology and translational medicine units at Brigham and Women’s Hospital, and a professor at Harvard Medical School. When he died, Dr. Stossel was chief scientific officer of BioAegis Therapeutics, a company he cofounded.
Dr. Stossel also cofounded Options for Children in Zambia, a charity that works with Zambian partners to provide preventive dental and medical care. And he helped establish a sickle cell disease clinical and research center at University Teaching Hospital in Lusaka.
In happier news, Jeff Vacirca, MD, recently won the 2019 American Red Cross Greater New York Region’s Humanitarian Award. Dr. Vacirca received the award at the 2019 Heroes Among Us Gala on Oct. 16.
Dr. Vacirca is chief executive officer of New York Cancer & Blood Specialists. He is also a consulting physician for the Long Island Association for AIDS Care, medical director for AmerisourceBergen specialty group, a scientific advisory board member for Caris Life Sciences, director at OneOncology, director at Spectrum Pharmaceuticals, a medical board adviser for Flatiron Health, and vice-chairman of the board for Odonate Therapeutics, a company he cofounded in 2016. In 2014, Dr. Vacirca founded the New York Cancer Foundation, which provides financial assistance to patients undergoing cancer treatment.
Another award winner is Richard J. Bleicher, MD, who has won the 2020 Jamie Brooke Lieberman Remembrance Award from Susan G. Komen Philadelphia for his work related to breast cancer. Dr. Bleicher is scheduled to receive his award at the Susan G. Komen Philadelphia MORE THAN PINK Walk Kickoff event on March 18, 2020.
Dr. Bleicher is a professor, breast cancer surgeon, and clinical researcher at Fox Chase Cancer Center in Philadelphia. He is director of the breast fellowship and leader of the breast cancer program at Fox Chase. He sits on the board of the National Accreditation Program for Breast Centers and the Quality Improvement Committee, sits on the Commission for Cancer’s Operative Standards Committee, and is the vice-chair for the Society of Surgical Oncology’s breast fellowship programs for the United States and Canada.
Thomas Peter Stossel, MD, a physician-researcher known for his discovery of cellular proteins and advocacy for academic-industry relationships, died unexpectedly on Sept. 29 at the age of 78.
Dr. Stossel’s research was largely focused on cell motility. He is known for discovering the cellular proteins filamin and gelsolin, which regulate the assembly of actin. Dr. Stossel is also known for promoting relationships between physicians and industry. He believed these relationships accelerate medical innovation.
Dr. Stossel graduated from Princeton University and Harvard Medical School. He served as chief of the hematology-oncology unit at Massachusetts General Hospital, head of experimental medicine and codirector of the hematology and translational medicine units at Brigham and Women’s Hospital, and a professor at Harvard Medical School. When he died, Dr. Stossel was chief scientific officer of BioAegis Therapeutics, a company he cofounded.
Dr. Stossel also cofounded Options for Children in Zambia, a charity that works with Zambian partners to provide preventive dental and medical care. And he helped establish a sickle cell disease clinical and research center at University Teaching Hospital in Lusaka.
In happier news, Jeff Vacirca, MD, recently won the 2019 American Red Cross Greater New York Region’s Humanitarian Award. Dr. Vacirca received the award at the 2019 Heroes Among Us Gala on Oct. 16.
Dr. Vacirca is chief executive officer of New York Cancer & Blood Specialists. He is also a consulting physician for the Long Island Association for AIDS Care, medical director for AmerisourceBergen specialty group, a scientific advisory board member for Caris Life Sciences, director at OneOncology, director at Spectrum Pharmaceuticals, a medical board adviser for Flatiron Health, and vice-chairman of the board for Odonate Therapeutics, a company he cofounded in 2016. In 2014, Dr. Vacirca founded the New York Cancer Foundation, which provides financial assistance to patients undergoing cancer treatment.
Another award winner is Richard J. Bleicher, MD, who has won the 2020 Jamie Brooke Lieberman Remembrance Award from Susan G. Komen Philadelphia for his work related to breast cancer. Dr. Bleicher is scheduled to receive his award at the Susan G. Komen Philadelphia MORE THAN PINK Walk Kickoff event on March 18, 2020.
Dr. Bleicher is a professor, breast cancer surgeon, and clinical researcher at Fox Chase Cancer Center in Philadelphia. He is director of the breast fellowship and leader of the breast cancer program at Fox Chase. He sits on the board of the National Accreditation Program for Breast Centers and the Quality Improvement Committee, sits on the Commission for Cancer’s Operative Standards Committee, and is the vice-chair for the Society of Surgical Oncology’s breast fellowship programs for the United States and Canada.
Thomas Peter Stossel, MD, a physician-researcher known for his discovery of cellular proteins and advocacy for academic-industry relationships, died unexpectedly on Sept. 29 at the age of 78.
Dr. Stossel’s research was largely focused on cell motility. He is known for discovering the cellular proteins filamin and gelsolin, which regulate the assembly of actin. Dr. Stossel is also known for promoting relationships between physicians and industry. He believed these relationships accelerate medical innovation.
Dr. Stossel graduated from Princeton University and Harvard Medical School. He served as chief of the hematology-oncology unit at Massachusetts General Hospital, head of experimental medicine and codirector of the hematology and translational medicine units at Brigham and Women’s Hospital, and a professor at Harvard Medical School. When he died, Dr. Stossel was chief scientific officer of BioAegis Therapeutics, a company he cofounded.
Dr. Stossel also cofounded Options for Children in Zambia, a charity that works with Zambian partners to provide preventive dental and medical care. And he helped establish a sickle cell disease clinical and research center at University Teaching Hospital in Lusaka.
In happier news, Jeff Vacirca, MD, recently won the 2019 American Red Cross Greater New York Region’s Humanitarian Award. Dr. Vacirca received the award at the 2019 Heroes Among Us Gala on Oct. 16.
Dr. Vacirca is chief executive officer of New York Cancer & Blood Specialists. He is also a consulting physician for the Long Island Association for AIDS Care, medical director for AmerisourceBergen specialty group, a scientific advisory board member for Caris Life Sciences, director at OneOncology, director at Spectrum Pharmaceuticals, a medical board adviser for Flatiron Health, and vice-chairman of the board for Odonate Therapeutics, a company he cofounded in 2016. In 2014, Dr. Vacirca founded the New York Cancer Foundation, which provides financial assistance to patients undergoing cancer treatment.
Another award winner is Richard J. Bleicher, MD, who has won the 2020 Jamie Brooke Lieberman Remembrance Award from Susan G. Komen Philadelphia for his work related to breast cancer. Dr. Bleicher is scheduled to receive his award at the Susan G. Komen Philadelphia MORE THAN PINK Walk Kickoff event on March 18, 2020.
Dr. Bleicher is a professor, breast cancer surgeon, and clinical researcher at Fox Chase Cancer Center in Philadelphia. He is director of the breast fellowship and leader of the breast cancer program at Fox Chase. He sits on the board of the National Accreditation Program for Breast Centers and the Quality Improvement Committee, sits on the Commission for Cancer’s Operative Standards Committee, and is the vice-chair for the Society of Surgical Oncology’s breast fellowship programs for the United States and Canada.
Cleveland Clinic taps Abraham as chair
Jame Abraham, MD, has been appointed chair of the hematology/medical oncology department at Cleveland Clinic in Ohio. In this new role, Dr. Abraham will “recruit and develop staff and guide the department’s focus on patient access and a multidisciplinary approach to care,” according to a statement.
Dr. Abraham is also director of the breast oncology program at Taussig Cancer Institute, codirector of the Cleveland Clinic comprehensive breast cancer program, and a professor of medicine at Cleveland Clinic Lerner College of Medicine. He takes the helm from hematologist Matt Kalaycio, MD. Dr. Kalaycio also serves as editor-in-chief of Hematology News.
In other news, Zhe Ying, PhD, of the Fred Hutchinson Cancer Research Center in Seattle, has received a 5-year Pathway to Independence Award from the National Institute of Dental and Craniofacial Research.
With this award funding, Dr. Ying will investigate oncogene-induced differentiation in PI3K-mutant head and neck squamous cell carcinoma. Specifically, he aims to determine if genetic mutations and niche factors can overcome oncogene-induced differentiation to promote tumorigenesis.
Another grant winner is Gina Mantia-Smaldone, MD, of Fox Chase Cancer Center in Philadelphia. She will receive 3 years of funding from the Gynecologic Oncology Group Foundation and NRG Oncology to study gynecologic malignancies.
This award will also provide Dr. Mantia-Smaldone with research mentorship and opportunities to collaborate with other researchers. Her research is focused on developing targeted therapies for ovarian and endometrial cancers that will, ideally, improve patients’ quality of life.
Lastly, Edna (Eti) Cukierman, PhD, of Fox Chase Cancer Center, received a grant to conduct research with Ashani Weeraratna, PhD, of Johns Hopkins University in Baltimore, and Vivek Shenoy, PhD, and Arjun Raj, PhD, both of the University of Pennsylvania in Philadelphia.
The grant, from the National Cancer Institute, will be used to investigate the link between cell aging and melanoma. Dr. Cukierman, Dr. Weeraratna, Dr. Shenoy, and Dr. Raj will focus their research "on better understanding the deterioration of collagen integrity via cellular aging and its role in melanoma metastasis,” according to a statement.
Jame Abraham, MD, has been appointed chair of the hematology/medical oncology department at Cleveland Clinic in Ohio. In this new role, Dr. Abraham will “recruit and develop staff and guide the department’s focus on patient access and a multidisciplinary approach to care,” according to a statement.
Dr. Abraham is also director of the breast oncology program at Taussig Cancer Institute, codirector of the Cleveland Clinic comprehensive breast cancer program, and a professor of medicine at Cleveland Clinic Lerner College of Medicine. He takes the helm from hematologist Matt Kalaycio, MD. Dr. Kalaycio also serves as editor-in-chief of Hematology News.
In other news, Zhe Ying, PhD, of the Fred Hutchinson Cancer Research Center in Seattle, has received a 5-year Pathway to Independence Award from the National Institute of Dental and Craniofacial Research.
With this award funding, Dr. Ying will investigate oncogene-induced differentiation in PI3K-mutant head and neck squamous cell carcinoma. Specifically, he aims to determine if genetic mutations and niche factors can overcome oncogene-induced differentiation to promote tumorigenesis.
Another grant winner is Gina Mantia-Smaldone, MD, of Fox Chase Cancer Center in Philadelphia. She will receive 3 years of funding from the Gynecologic Oncology Group Foundation and NRG Oncology to study gynecologic malignancies.
This award will also provide Dr. Mantia-Smaldone with research mentorship and opportunities to collaborate with other researchers. Her research is focused on developing targeted therapies for ovarian and endometrial cancers that will, ideally, improve patients’ quality of life.
Lastly, Edna (Eti) Cukierman, PhD, of Fox Chase Cancer Center, received a grant to conduct research with Ashani Weeraratna, PhD, of Johns Hopkins University in Baltimore, and Vivek Shenoy, PhD, and Arjun Raj, PhD, both of the University of Pennsylvania in Philadelphia.
The grant, from the National Cancer Institute, will be used to investigate the link between cell aging and melanoma. Dr. Cukierman, Dr. Weeraratna, Dr. Shenoy, and Dr. Raj will focus their research "on better understanding the deterioration of collagen integrity via cellular aging and its role in melanoma metastasis,” according to a statement.
Jame Abraham, MD, has been appointed chair of the hematology/medical oncology department at Cleveland Clinic in Ohio. In this new role, Dr. Abraham will “recruit and develop staff and guide the department’s focus on patient access and a multidisciplinary approach to care,” according to a statement.
Dr. Abraham is also director of the breast oncology program at Taussig Cancer Institute, codirector of the Cleveland Clinic comprehensive breast cancer program, and a professor of medicine at Cleveland Clinic Lerner College of Medicine. He takes the helm from hematologist Matt Kalaycio, MD. Dr. Kalaycio also serves as editor-in-chief of Hematology News.
In other news, Zhe Ying, PhD, of the Fred Hutchinson Cancer Research Center in Seattle, has received a 5-year Pathway to Independence Award from the National Institute of Dental and Craniofacial Research.
With this award funding, Dr. Ying will investigate oncogene-induced differentiation in PI3K-mutant head and neck squamous cell carcinoma. Specifically, he aims to determine if genetic mutations and niche factors can overcome oncogene-induced differentiation to promote tumorigenesis.
Another grant winner is Gina Mantia-Smaldone, MD, of Fox Chase Cancer Center in Philadelphia. She will receive 3 years of funding from the Gynecologic Oncology Group Foundation and NRG Oncology to study gynecologic malignancies.
This award will also provide Dr. Mantia-Smaldone with research mentorship and opportunities to collaborate with other researchers. Her research is focused on developing targeted therapies for ovarian and endometrial cancers that will, ideally, improve patients’ quality of life.
Lastly, Edna (Eti) Cukierman, PhD, of Fox Chase Cancer Center, received a grant to conduct research with Ashani Weeraratna, PhD, of Johns Hopkins University in Baltimore, and Vivek Shenoy, PhD, and Arjun Raj, PhD, both of the University of Pennsylvania in Philadelphia.
The grant, from the National Cancer Institute, will be used to investigate the link between cell aging and melanoma. Dr. Cukierman, Dr. Weeraratna, Dr. Shenoy, and Dr. Raj will focus their research "on better understanding the deterioration of collagen integrity via cellular aging and its role in melanoma metastasis,” according to a statement.
Multiple Myeloma Research Consortium, cancer centers add new leaders
Hearn Jay Cho, MD, PhD, has been appointed chief medical officer of the Multiple Myeloma Research Foundation (MMRF). In this role, Dr. Cho will develop a clinical research strategy and accelerate drug development programs for the MMRF. He will also lead the Multiple Myeloma Research Consortium, a group of 25 research centers focused on multiple myeloma.
Dr. Cho will continue on as an associate professor of medicine at the Icahn School of Medicine at Mt. Sinai in New York, and as an attending physician with the multiple myeloma service at the Mt. Sinai Tisch Cancer Institute. He will also continue to manage his lab at Mt. Sinai.
Michael Jay Styler, MD, has joined the department of hematology/oncology as an associate professor in the academic clinician track as part of the bone marrow transplant program at Fox Chase Cancer Center in Philadelphia.
Dr. Styler was previously medical director of the transplant center, apheresis center, and collection center at Hahnemann University Hospital in Philadelphia, as well as medical director of the stem cell transplant program and the clinical service chief of hematology/oncology. Dr. Styler was also an associate professor at Drexel University, Philadelphia, where he served as division director of hematology/oncology and associate fellowship director of the hematology/oncology program.
Jaspreet Chahal, MD, has joined the Oncology Institute of Hope and Innovation, which has locations in Arizona, California, and Nevada. Dr. Chahal will serve patients in Tucson and Green Valley, Ariz.
Dr. Chahal has a doctor of medicine degree from St. George’s University in West Indies, Grenada. She completed her internship in hematology and oncology at Hofstra University, Hempstead, N.Y., and her residency in internal medicine at the University of Arizona in Tucson.
Marcin Chwistek, MD, has been appointed editor in chief of AAHPM Quarterly, which is published by the American Academy of Hospice and Palliative Medicine. Dr. Chwistek is an associate professor in the department of hematology/oncology at Fox Chase Cancer Center in Philadelphia, where he is also director of the pain and palliative care program.
As editor in chief of AAHPM Quarterly, Dr. Chwistek will work with other members of the editorial board to develop content related to hospice care and palliative medicine. Dr. Chwistek previously served as the associate editor in chief of AAHPM Quarterly and writes a column that appears in every issue.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com , and you could be featured in Movers in Medicine.
Hearn Jay Cho, MD, PhD, has been appointed chief medical officer of the Multiple Myeloma Research Foundation (MMRF). In this role, Dr. Cho will develop a clinical research strategy and accelerate drug development programs for the MMRF. He will also lead the Multiple Myeloma Research Consortium, a group of 25 research centers focused on multiple myeloma.
Dr. Cho will continue on as an associate professor of medicine at the Icahn School of Medicine at Mt. Sinai in New York, and as an attending physician with the multiple myeloma service at the Mt. Sinai Tisch Cancer Institute. He will also continue to manage his lab at Mt. Sinai.
Michael Jay Styler, MD, has joined the department of hematology/oncology as an associate professor in the academic clinician track as part of the bone marrow transplant program at Fox Chase Cancer Center in Philadelphia.
Dr. Styler was previously medical director of the transplant center, apheresis center, and collection center at Hahnemann University Hospital in Philadelphia, as well as medical director of the stem cell transplant program and the clinical service chief of hematology/oncology. Dr. Styler was also an associate professor at Drexel University, Philadelphia, where he served as division director of hematology/oncology and associate fellowship director of the hematology/oncology program.
Jaspreet Chahal, MD, has joined the Oncology Institute of Hope and Innovation, which has locations in Arizona, California, and Nevada. Dr. Chahal will serve patients in Tucson and Green Valley, Ariz.
Dr. Chahal has a doctor of medicine degree from St. George’s University in West Indies, Grenada. She completed her internship in hematology and oncology at Hofstra University, Hempstead, N.Y., and her residency in internal medicine at the University of Arizona in Tucson.
Marcin Chwistek, MD, has been appointed editor in chief of AAHPM Quarterly, which is published by the American Academy of Hospice and Palliative Medicine. Dr. Chwistek is an associate professor in the department of hematology/oncology at Fox Chase Cancer Center in Philadelphia, where he is also director of the pain and palliative care program.
As editor in chief of AAHPM Quarterly, Dr. Chwistek will work with other members of the editorial board to develop content related to hospice care and palliative medicine. Dr. Chwistek previously served as the associate editor in chief of AAHPM Quarterly and writes a column that appears in every issue.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com , and you could be featured in Movers in Medicine.
Hearn Jay Cho, MD, PhD, has been appointed chief medical officer of the Multiple Myeloma Research Foundation (MMRF). In this role, Dr. Cho will develop a clinical research strategy and accelerate drug development programs for the MMRF. He will also lead the Multiple Myeloma Research Consortium, a group of 25 research centers focused on multiple myeloma.
Dr. Cho will continue on as an associate professor of medicine at the Icahn School of Medicine at Mt. Sinai in New York, and as an attending physician with the multiple myeloma service at the Mt. Sinai Tisch Cancer Institute. He will also continue to manage his lab at Mt. Sinai.
Michael Jay Styler, MD, has joined the department of hematology/oncology as an associate professor in the academic clinician track as part of the bone marrow transplant program at Fox Chase Cancer Center in Philadelphia.
Dr. Styler was previously medical director of the transplant center, apheresis center, and collection center at Hahnemann University Hospital in Philadelphia, as well as medical director of the stem cell transplant program and the clinical service chief of hematology/oncology. Dr. Styler was also an associate professor at Drexel University, Philadelphia, where he served as division director of hematology/oncology and associate fellowship director of the hematology/oncology program.
Jaspreet Chahal, MD, has joined the Oncology Institute of Hope and Innovation, which has locations in Arizona, California, and Nevada. Dr. Chahal will serve patients in Tucson and Green Valley, Ariz.
Dr. Chahal has a doctor of medicine degree from St. George’s University in West Indies, Grenada. She completed her internship in hematology and oncology at Hofstra University, Hempstead, N.Y., and her residency in internal medicine at the University of Arizona in Tucson.
Marcin Chwistek, MD, has been appointed editor in chief of AAHPM Quarterly, which is published by the American Academy of Hospice and Palliative Medicine. Dr. Chwistek is an associate professor in the department of hematology/oncology at Fox Chase Cancer Center in Philadelphia, where he is also director of the pain and palliative care program.
As editor in chief of AAHPM Quarterly, Dr. Chwistek will work with other members of the editorial board to develop content related to hospice care and palliative medicine. Dr. Chwistek previously served as the associate editor in chief of AAHPM Quarterly and writes a column that appears in every issue.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com , and you could be featured in Movers in Medicine.
Fox Chase faculty receive grants for cancer research, education
Faculty members at Fox Chase Cancer Center have received grants to promote education about liver cancer, study pancreatic and breast cancer, and examine burnout among physician assistants (PAs).
Eric D. Tetzlaff, a PA at Fox Chase in Philadelphia, has received a 3-year grant from the Association of Physician Assistants in Oncology. With this $15,000 grant, Mr. Tetzlaff plans to conduct a longitudinal study that will explore burnout among PAs working in oncology.
The goals of his study are to “understand the impact of the attitudes of oncology PAs regarding teamwork, expectations for their professional role, type of collaborative practice, organizational context of the job environment, and moral distress, on burnout and career satisfaction,” according to Fox Chase.
Jaye Gardiner, PhD, a postdoctoral researcher in the Edna Cukierman laboratory at Fox Chase, has received a $163,500 grant from the American Cancer Society. With this grant, Dr. Gardiner will investigate the role of tumor stroma in pancreatic cancer.
Dr. Gardiner plans to explore how cancer-associated fibroblasts in the pancreatic stroma “communicate with one another and how this communication is altered in tumor-promoting versus tumor-restricting conditions,” according to Fox Chase.
Dietmar J. Kappes, PhD, a professor of blood cell development and cancer and director of the Transgenic Mouse Facility at Fox Chase, has received a 5-year grant from the National Institutes of Health. With this $626,072 grant, Dr. Kappes will investigate the role of the transcription factor ThPOK in breast cancer.
Dr. Kappes and colleagues previously found a link between high cytoplasmic levels of ThPOK and poor outcomes in breast cancer. Now, Dr. Kappes plans to “further elucidate the role of ThPOK in breast cancer by combining novel animal models and molecular approaches,” according to Fox Chase.
Evelyn González, senior director of the Fox Chase’s Office of Community Outreach, and Shannon Lynch, PhD, who is with the Cancer Prevention and Control program, have received a 2-year grant from the Pennsylvania Department of Human Services.
The pair will use this $125,000 grant to provide liver cancer and hepatitis education to communities in the Philadelphia area with the greatest burden of liver cancer and related risk factors. Dr. Lynch will find these at-risk communities, and the Office of Community Outreach will work with partner groups in those areas to provide bilingual education about hepatitis and how it relates to liver cancer.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
Faculty members at Fox Chase Cancer Center have received grants to promote education about liver cancer, study pancreatic and breast cancer, and examine burnout among physician assistants (PAs).
Eric D. Tetzlaff, a PA at Fox Chase in Philadelphia, has received a 3-year grant from the Association of Physician Assistants in Oncology. With this $15,000 grant, Mr. Tetzlaff plans to conduct a longitudinal study that will explore burnout among PAs working in oncology.
The goals of his study are to “understand the impact of the attitudes of oncology PAs regarding teamwork, expectations for their professional role, type of collaborative practice, organizational context of the job environment, and moral distress, on burnout and career satisfaction,” according to Fox Chase.
Jaye Gardiner, PhD, a postdoctoral researcher in the Edna Cukierman laboratory at Fox Chase, has received a $163,500 grant from the American Cancer Society. With this grant, Dr. Gardiner will investigate the role of tumor stroma in pancreatic cancer.
Dr. Gardiner plans to explore how cancer-associated fibroblasts in the pancreatic stroma “communicate with one another and how this communication is altered in tumor-promoting versus tumor-restricting conditions,” according to Fox Chase.
Dietmar J. Kappes, PhD, a professor of blood cell development and cancer and director of the Transgenic Mouse Facility at Fox Chase, has received a 5-year grant from the National Institutes of Health. With this $626,072 grant, Dr. Kappes will investigate the role of the transcription factor ThPOK in breast cancer.
Dr. Kappes and colleagues previously found a link between high cytoplasmic levels of ThPOK and poor outcomes in breast cancer. Now, Dr. Kappes plans to “further elucidate the role of ThPOK in breast cancer by combining novel animal models and molecular approaches,” according to Fox Chase.
Evelyn González, senior director of the Fox Chase’s Office of Community Outreach, and Shannon Lynch, PhD, who is with the Cancer Prevention and Control program, have received a 2-year grant from the Pennsylvania Department of Human Services.
The pair will use this $125,000 grant to provide liver cancer and hepatitis education to communities in the Philadelphia area with the greatest burden of liver cancer and related risk factors. Dr. Lynch will find these at-risk communities, and the Office of Community Outreach will work with partner groups in those areas to provide bilingual education about hepatitis and how it relates to liver cancer.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
Faculty members at Fox Chase Cancer Center have received grants to promote education about liver cancer, study pancreatic and breast cancer, and examine burnout among physician assistants (PAs).
Eric D. Tetzlaff, a PA at Fox Chase in Philadelphia, has received a 3-year grant from the Association of Physician Assistants in Oncology. With this $15,000 grant, Mr. Tetzlaff plans to conduct a longitudinal study that will explore burnout among PAs working in oncology.
The goals of his study are to “understand the impact of the attitudes of oncology PAs regarding teamwork, expectations for their professional role, type of collaborative practice, organizational context of the job environment, and moral distress, on burnout and career satisfaction,” according to Fox Chase.
Jaye Gardiner, PhD, a postdoctoral researcher in the Edna Cukierman laboratory at Fox Chase, has received a $163,500 grant from the American Cancer Society. With this grant, Dr. Gardiner will investigate the role of tumor stroma in pancreatic cancer.
Dr. Gardiner plans to explore how cancer-associated fibroblasts in the pancreatic stroma “communicate with one another and how this communication is altered in tumor-promoting versus tumor-restricting conditions,” according to Fox Chase.
Dietmar J. Kappes, PhD, a professor of blood cell development and cancer and director of the Transgenic Mouse Facility at Fox Chase, has received a 5-year grant from the National Institutes of Health. With this $626,072 grant, Dr. Kappes will investigate the role of the transcription factor ThPOK in breast cancer.
Dr. Kappes and colleagues previously found a link between high cytoplasmic levels of ThPOK and poor outcomes in breast cancer. Now, Dr. Kappes plans to “further elucidate the role of ThPOK in breast cancer by combining novel animal models and molecular approaches,” according to Fox Chase.
Evelyn González, senior director of the Fox Chase’s Office of Community Outreach, and Shannon Lynch, PhD, who is with the Cancer Prevention and Control program, have received a 2-year grant from the Pennsylvania Department of Human Services.
The pair will use this $125,000 grant to provide liver cancer and hepatitis education to communities in the Philadelphia area with the greatest burden of liver cancer and related risk factors. Dr. Lynch will find these at-risk communities, and the Office of Community Outreach will work with partner groups in those areas to provide bilingual education about hepatitis and how it relates to liver cancer.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
Researchers win grants to study real-world cancer data
Three researchers have won CancerLinQ Discovery Research Support Grants from the American Society of Clinical Oncology, and two researchers have received a National Institutes of Health R21 grant.
Igor Astsaturov, MD, PhD, and Edna Cukierman, PhD, both of Fox Chase Cancer Center in Philadelphia, won the R21 grant. The pair will receive $432,410 over 2 years for their research on pancreatic cancer.
With their work, Dr. Astsaturov and Dr. Cukierman are “hoping to describe the structural and functional nature of cell-cell contact, or oncogenic synapses, associated with cancer-associated fibroblasts and pancreatic cells,” according to Fox Chase.
Three other researchers have won ASCO’s CancerLinQ Discovery Research Support Grants. The recipients will conduct projects using CancerLinQ, which collects and analyzes real-world data from cancer patients at practices across the United States.
Each 1-year grant covers the cost of a CancerLinQ Discovery data set and a meeting at ASCO headquarters. The grants also contribute to personnel and/or research expenses. The grants are funded by the ASCO Foundation’s Mission Endowment of Conquer Cancer.
With his CancerLinQ Discovery grant, Sadiq Rehmani, MD, of Icahn School of Medicine at Mount Sinai in New York, will study immunotherapy in older lung cancer patients with comorbidities.
Grant recipient Yasmin Karimi, MD, of Stanford (Calif.) University, will study how osteoclast inhibitors affect skeletal-related events and mortality in “real-world” patients with metastatic breast cancer and bone metastasis.
Grant recipient Vinayak Muralidhar, MD, of Brigham and Women’s Hospital and the radiation oncology program at Harvard Medical School, Boston, will study the use of androgen-deprivation therapy and hypofractionation in prostate cancer.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
Three researchers have won CancerLinQ Discovery Research Support Grants from the American Society of Clinical Oncology, and two researchers have received a National Institutes of Health R21 grant.
Igor Astsaturov, MD, PhD, and Edna Cukierman, PhD, both of Fox Chase Cancer Center in Philadelphia, won the R21 grant. The pair will receive $432,410 over 2 years for their research on pancreatic cancer.
With their work, Dr. Astsaturov and Dr. Cukierman are “hoping to describe the structural and functional nature of cell-cell contact, or oncogenic synapses, associated with cancer-associated fibroblasts and pancreatic cells,” according to Fox Chase.
Three other researchers have won ASCO’s CancerLinQ Discovery Research Support Grants. The recipients will conduct projects using CancerLinQ, which collects and analyzes real-world data from cancer patients at practices across the United States.
Each 1-year grant covers the cost of a CancerLinQ Discovery data set and a meeting at ASCO headquarters. The grants also contribute to personnel and/or research expenses. The grants are funded by the ASCO Foundation’s Mission Endowment of Conquer Cancer.
With his CancerLinQ Discovery grant, Sadiq Rehmani, MD, of Icahn School of Medicine at Mount Sinai in New York, will study immunotherapy in older lung cancer patients with comorbidities.
Grant recipient Yasmin Karimi, MD, of Stanford (Calif.) University, will study how osteoclast inhibitors affect skeletal-related events and mortality in “real-world” patients with metastatic breast cancer and bone metastasis.
Grant recipient Vinayak Muralidhar, MD, of Brigham and Women’s Hospital and the radiation oncology program at Harvard Medical School, Boston, will study the use of androgen-deprivation therapy and hypofractionation in prostate cancer.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
Three researchers have won CancerLinQ Discovery Research Support Grants from the American Society of Clinical Oncology, and two researchers have received a National Institutes of Health R21 grant.
Igor Astsaturov, MD, PhD, and Edna Cukierman, PhD, both of Fox Chase Cancer Center in Philadelphia, won the R21 grant. The pair will receive $432,410 over 2 years for their research on pancreatic cancer.
With their work, Dr. Astsaturov and Dr. Cukierman are “hoping to describe the structural and functional nature of cell-cell contact, or oncogenic synapses, associated with cancer-associated fibroblasts and pancreatic cells,” according to Fox Chase.
Three other researchers have won ASCO’s CancerLinQ Discovery Research Support Grants. The recipients will conduct projects using CancerLinQ, which collects and analyzes real-world data from cancer patients at practices across the United States.
Each 1-year grant covers the cost of a CancerLinQ Discovery data set and a meeting at ASCO headquarters. The grants also contribute to personnel and/or research expenses. The grants are funded by the ASCO Foundation’s Mission Endowment of Conquer Cancer.
With his CancerLinQ Discovery grant, Sadiq Rehmani, MD, of Icahn School of Medicine at Mount Sinai in New York, will study immunotherapy in older lung cancer patients with comorbidities.
Grant recipient Yasmin Karimi, MD, of Stanford (Calif.) University, will study how osteoclast inhibitors affect skeletal-related events and mortality in “real-world” patients with metastatic breast cancer and bone metastasis.
Grant recipient Vinayak Muralidhar, MD, of Brigham and Women’s Hospital and the radiation oncology program at Harvard Medical School, Boston, will study the use of androgen-deprivation therapy and hypofractionation in prostate cancer.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
Cancer centers announce new faculty
Jorge E. Cortes, MD, is set to become director of the Georgia Cancer Center in Augusta on Sept. 1. In this new position, Dr. Cortes will further the center’s missions of obtaining National Cancer Institute designation and reducing the burden of cancer in Georgia.
Dr. Cortes was previously deputy chair and professor of medicine in the department of leukemia at MD Anderson Cancer Center in Houston. He received his medical degree in 1986 and began working at MD Anderson in 1991. His clinical interests include acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms.
Fern M. Anari, MD, joined Fox Chase Cancer Center in Philadelphia in August. Dr. Anari is now an assistant professor in the division of genitourinary medical oncology within the department of hematology/oncology.
Dr. Anari earned her medical degree from Robert Wood Johnson Medical School in New Brunswick, N.J., and completed an internship and residency at Thomas Jefferson University Hospital in Philadelphia. She joined Fox Chase/Temple University for a 3-year fellowship in 2016.
Another new hire in the department of hematology/oncology at Fox Chase is Iberia Romina Sosa, MD, PhD. Dr. Sosa became an assistant professor in the clinical investigator track in August.
Dr. Sosa, who is a member of the Hematology News editorial advisory board, was previously an assistant professor in the department of hematology/oncology at Baylor College of Medicine in Houston. She received her MD and PhD from the University of Minnesota in Minneapolis and completed a residency and fellowship at Vanderbilt University in Nashville, Tenn.
Finally, John Migliano, MD, has joined The Oncology Institute of Hope and Innovation, which has locations in Southern California, Arizona, and Nevada. Dr. Migliano serves patients at the Arizona locations in Tucson, Oro Valley, and Marana.
Dr. Migliano received his medical degree from the University of Medicine and Health Sciences in Saint Kitts and completed his residency in internal medicine at the University of Arizona in Tucson. He was a hematology/oncology fellow at Wake Forest University Baptist Medical Center in Winston-Salem, N.C.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
Jorge E. Cortes, MD, is set to become director of the Georgia Cancer Center in Augusta on Sept. 1. In this new position, Dr. Cortes will further the center’s missions of obtaining National Cancer Institute designation and reducing the burden of cancer in Georgia.
Dr. Cortes was previously deputy chair and professor of medicine in the department of leukemia at MD Anderson Cancer Center in Houston. He received his medical degree in 1986 and began working at MD Anderson in 1991. His clinical interests include acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms.
Fern M. Anari, MD, joined Fox Chase Cancer Center in Philadelphia in August. Dr. Anari is now an assistant professor in the division of genitourinary medical oncology within the department of hematology/oncology.
Dr. Anari earned her medical degree from Robert Wood Johnson Medical School in New Brunswick, N.J., and completed an internship and residency at Thomas Jefferson University Hospital in Philadelphia. She joined Fox Chase/Temple University for a 3-year fellowship in 2016.
Another new hire in the department of hematology/oncology at Fox Chase is Iberia Romina Sosa, MD, PhD. Dr. Sosa became an assistant professor in the clinical investigator track in August.
Dr. Sosa, who is a member of the Hematology News editorial advisory board, was previously an assistant professor in the department of hematology/oncology at Baylor College of Medicine in Houston. She received her MD and PhD from the University of Minnesota in Minneapolis and completed a residency and fellowship at Vanderbilt University in Nashville, Tenn.
Finally, John Migliano, MD, has joined The Oncology Institute of Hope and Innovation, which has locations in Southern California, Arizona, and Nevada. Dr. Migliano serves patients at the Arizona locations in Tucson, Oro Valley, and Marana.
Dr. Migliano received his medical degree from the University of Medicine and Health Sciences in Saint Kitts and completed his residency in internal medicine at the University of Arizona in Tucson. He was a hematology/oncology fellow at Wake Forest University Baptist Medical Center in Winston-Salem, N.C.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
Jorge E. Cortes, MD, is set to become director of the Georgia Cancer Center in Augusta on Sept. 1. In this new position, Dr. Cortes will further the center’s missions of obtaining National Cancer Institute designation and reducing the burden of cancer in Georgia.
Dr. Cortes was previously deputy chair and professor of medicine in the department of leukemia at MD Anderson Cancer Center in Houston. He received his medical degree in 1986 and began working at MD Anderson in 1991. His clinical interests include acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms.
Fern M. Anari, MD, joined Fox Chase Cancer Center in Philadelphia in August. Dr. Anari is now an assistant professor in the division of genitourinary medical oncology within the department of hematology/oncology.
Dr. Anari earned her medical degree from Robert Wood Johnson Medical School in New Brunswick, N.J., and completed an internship and residency at Thomas Jefferson University Hospital in Philadelphia. She joined Fox Chase/Temple University for a 3-year fellowship in 2016.
Another new hire in the department of hematology/oncology at Fox Chase is Iberia Romina Sosa, MD, PhD. Dr. Sosa became an assistant professor in the clinical investigator track in August.
Dr. Sosa, who is a member of the Hematology News editorial advisory board, was previously an assistant professor in the department of hematology/oncology at Baylor College of Medicine in Houston. She received her MD and PhD from the University of Minnesota in Minneapolis and completed a residency and fellowship at Vanderbilt University in Nashville, Tenn.
Finally, John Migliano, MD, has joined The Oncology Institute of Hope and Innovation, which has locations in Southern California, Arizona, and Nevada. Dr. Migliano serves patients at the Arizona locations in Tucson, Oro Valley, and Marana.
Dr. Migliano received his medical degree from the University of Medicine and Health Sciences in Saint Kitts and completed his residency in internal medicine at the University of Arizona in Tucson. He was a hematology/oncology fellow at Wake Forest University Baptist Medical Center in Winston-Salem, N.C.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
ASTRO announces new president-elect, board members
The American Society for Radiation Oncology (ASTRO) has elected a new president-elect and three new officers to its board of directors.
The incoming president-elect is Laura Dawson, MD, of Princess Margaret Cancer Centre and University of Toronto. Dr. Dawson is a professor and radiation oncologist specializing in gastrointestinal malignancies with a focus on hepatobiliary carcinoma and liver metastases, stereotactic body radiation therapy, image-guided radiation therapy, and normal tissue radiation toxicity.
Dr. Dawson will begin her term in September 2019 during ASTRO’s 61st annual meeting. She will serve a 1-year term as president-elect, a 1-year term as president, and a 1-year term as chair of the ASTRO board. During her tenure, Dr. Dawson plans to address issues such as physician burnout, restrictive prior authorization practices, and diversity in the workforce.
Neha Vapiwala, MD, is ASTRO’s new secretary/treasurer-elect. Dr. Vapiwala is an associate professor, vice-chair of education in the department of radiation oncology, and dean of admissions at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia.
She specializes in the management of patients with genitourinary cancers, and her research is focused on improving the delivery of photon- and proton-based radiation.
Dr. Vapiwala will serve a 1-year term as ASTRO’s secretary/treasurer-elect followed by a 3-year term as secretary/treasurer. In these roles, she plans to address challenges in health care economics and assess the role of artificial intelligence and other new technologies in radiation oncology.
Constantine Mantz, MD, is ASTRO’s new Health Policy Council vice-chair. Dr. Mantz is chief policy officer and a radiation oncologist at 21st Century Oncology in Ft. Meyers, Fla.
He specializes in head and neck, prostate, breast, lung, and colorectal cancers.
Dr. Mantz will serve a 2-year term as vice-chair of the Health Policy Council followed by a 2-year term as chair. Dr. Mantz plans to address payment reform issues, including the implementation of an alternative payment model for radiation oncology.
Brian Marples, PhD, is ASTRO’s new Science Council vice-chair. Dr. Marples is a research professor and director of radiobiology in the department of radiation oncology at the University of Miami Miller School of Medicine. His research is focused on maximizing a tumor’s response to radiation while minimizing damage to normal tissue.
Dr. Marples will serve a 2-year term as vice-chair of the Science Council, followed by a 2-year term as chair. He plans to engage the medical community and the public in radiation oncology innovations, such as new technologies that combine radiation and immunotherapy.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
The American Society for Radiation Oncology (ASTRO) has elected a new president-elect and three new officers to its board of directors.
The incoming president-elect is Laura Dawson, MD, of Princess Margaret Cancer Centre and University of Toronto. Dr. Dawson is a professor and radiation oncologist specializing in gastrointestinal malignancies with a focus on hepatobiliary carcinoma and liver metastases, stereotactic body radiation therapy, image-guided radiation therapy, and normal tissue radiation toxicity.
Dr. Dawson will begin her term in September 2019 during ASTRO’s 61st annual meeting. She will serve a 1-year term as president-elect, a 1-year term as president, and a 1-year term as chair of the ASTRO board. During her tenure, Dr. Dawson plans to address issues such as physician burnout, restrictive prior authorization practices, and diversity in the workforce.
Neha Vapiwala, MD, is ASTRO’s new secretary/treasurer-elect. Dr. Vapiwala is an associate professor, vice-chair of education in the department of radiation oncology, and dean of admissions at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia.
She specializes in the management of patients with genitourinary cancers, and her research is focused on improving the delivery of photon- and proton-based radiation.
Dr. Vapiwala will serve a 1-year term as ASTRO’s secretary/treasurer-elect followed by a 3-year term as secretary/treasurer. In these roles, she plans to address challenges in health care economics and assess the role of artificial intelligence and other new technologies in radiation oncology.
Constantine Mantz, MD, is ASTRO’s new Health Policy Council vice-chair. Dr. Mantz is chief policy officer and a radiation oncologist at 21st Century Oncology in Ft. Meyers, Fla.
He specializes in head and neck, prostate, breast, lung, and colorectal cancers.
Dr. Mantz will serve a 2-year term as vice-chair of the Health Policy Council followed by a 2-year term as chair. Dr. Mantz plans to address payment reform issues, including the implementation of an alternative payment model for radiation oncology.
Brian Marples, PhD, is ASTRO’s new Science Council vice-chair. Dr. Marples is a research professor and director of radiobiology in the department of radiation oncology at the University of Miami Miller School of Medicine. His research is focused on maximizing a tumor’s response to radiation while minimizing damage to normal tissue.
Dr. Marples will serve a 2-year term as vice-chair of the Science Council, followed by a 2-year term as chair. He plans to engage the medical community and the public in radiation oncology innovations, such as new technologies that combine radiation and immunotherapy.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
The American Society for Radiation Oncology (ASTRO) has elected a new president-elect and three new officers to its board of directors.
The incoming president-elect is Laura Dawson, MD, of Princess Margaret Cancer Centre and University of Toronto. Dr. Dawson is a professor and radiation oncologist specializing in gastrointestinal malignancies with a focus on hepatobiliary carcinoma and liver metastases, stereotactic body radiation therapy, image-guided radiation therapy, and normal tissue radiation toxicity.
Dr. Dawson will begin her term in September 2019 during ASTRO’s 61st annual meeting. She will serve a 1-year term as president-elect, a 1-year term as president, and a 1-year term as chair of the ASTRO board. During her tenure, Dr. Dawson plans to address issues such as physician burnout, restrictive prior authorization practices, and diversity in the workforce.
Neha Vapiwala, MD, is ASTRO’s new secretary/treasurer-elect. Dr. Vapiwala is an associate professor, vice-chair of education in the department of radiation oncology, and dean of admissions at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia.
She specializes in the management of patients with genitourinary cancers, and her research is focused on improving the delivery of photon- and proton-based radiation.
Dr. Vapiwala will serve a 1-year term as ASTRO’s secretary/treasurer-elect followed by a 3-year term as secretary/treasurer. In these roles, she plans to address challenges in health care economics and assess the role of artificial intelligence and other new technologies in radiation oncology.
Constantine Mantz, MD, is ASTRO’s new Health Policy Council vice-chair. Dr. Mantz is chief policy officer and a radiation oncologist at 21st Century Oncology in Ft. Meyers, Fla.
He specializes in head and neck, prostate, breast, lung, and colorectal cancers.
Dr. Mantz will serve a 2-year term as vice-chair of the Health Policy Council followed by a 2-year term as chair. Dr. Mantz plans to address payment reform issues, including the implementation of an alternative payment model for radiation oncology.
Brian Marples, PhD, is ASTRO’s new Science Council vice-chair. Dr. Marples is a research professor and director of radiobiology in the department of radiation oncology at the University of Miami Miller School of Medicine. His research is focused on maximizing a tumor’s response to radiation while minimizing damage to normal tissue.
Dr. Marples will serve a 2-year term as vice-chair of the Science Council, followed by a 2-year term as chair. He plans to engage the medical community and the public in radiation oncology innovations, such as new technologies that combine radiation and immunotherapy.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
New appointments at City of Hope, UA, and Fox Chase
The University of Arizona (UA) Cancer Center has a new interim director, two hematologists have earned new positions at City of Hope, and an assistant professor has joined Fox Chase Cancer Center.
William Cance, MD, has been appointed interim director of the UA Cancer Center. In this role, he will oversee clinical operations and research at the center’s primary locations in Tucson and Phoenix. He will also lead the UA Cancer Center’s efforts to renew its 5-year Cancer Center Support Grant from the National Cancer Institute (NCI).
In addition to his new role, Dr. Cance is a professor at the UA Colleges of Medicine and Pharmacy in Phoenix. He is board certified in general surgery and specializes in thyroid cancer, parathyroid disease, sarcoma, and gastrointestinal cancer. Dr. Cance has received funding from NCI, has served on the NCI Board of Scientific Counselors, and is a member of NCI Subcommittee F.
In other news, Larry Kwak, MD, PhD, has been appointed the deputy director of the Hematologic Malignancies and Stem Cell Transplantation Institute at City of Hope in Duarte, Calif. Dr. Kwak will work with the director of the Institute, Stephen J. Forman, MD, to oversee recruitment, clinical and laboratory research, and faculty development.
Dr. Kwak is also director of the Toni Stephenson Lymphoma Center, vice president and deputy director of the comprehensive cancer center, and the Dr. Michael Friedman Professor in Translational Medicine. Dr. Kwak was named one of TIME magazine’s “100 Most Influential People,” received the Chang-Yul Oh Memorial Award from the Korean Medical Association, and won the Ho-Am Prize in Medicine.
Also at City of Hope, Tanya Siddiqi, MD, has been appointed director of the chronic lymphocytic leukemia (CLL) program within the Toni Stephenson Lymphoma Center of the Hematologic Malignancies and Stem Cell Transplantation Institute. In this role, Dr. Siddiqi will oversee research efforts related to CLL. This includes maintaining the CLL tissue bank she developed, conducting translational studies and clinical trials, and investigating novel therapies for CLL.
Dr. Siddiqi is also an associate clinical professor in the department of hematology & hematopoietic cell transplantation, is the supervising physician of City of Hope’s anticoagulation clinic, and works in the Gehr Family Center for Leukemia Research. Dr. Siddiqi is a member of the National Comprehensive Cancer Network panels for CLL/SLL/hairy cell leukemia and venous thromboembolism.
Lastly, James M. Martin, MD, has been appointed assistant professor in the hematology and bone marrow transplant program within the department of hematology/oncology at Fox Chase Cancer Center in Philadelphia.
Dr. Martin received a medical degree from Ohio State University, Columbus, and completed an internship and residency at Rhode Island Hospital/Brown University, in Providence. He joined Fox Chase Cancer Center/Temple University in 2016 for a 3-year fellowship.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
The University of Arizona (UA) Cancer Center has a new interim director, two hematologists have earned new positions at City of Hope, and an assistant professor has joined Fox Chase Cancer Center.
William Cance, MD, has been appointed interim director of the UA Cancer Center. In this role, he will oversee clinical operations and research at the center’s primary locations in Tucson and Phoenix. He will also lead the UA Cancer Center’s efforts to renew its 5-year Cancer Center Support Grant from the National Cancer Institute (NCI).
In addition to his new role, Dr. Cance is a professor at the UA Colleges of Medicine and Pharmacy in Phoenix. He is board certified in general surgery and specializes in thyroid cancer, parathyroid disease, sarcoma, and gastrointestinal cancer. Dr. Cance has received funding from NCI, has served on the NCI Board of Scientific Counselors, and is a member of NCI Subcommittee F.
In other news, Larry Kwak, MD, PhD, has been appointed the deputy director of the Hematologic Malignancies and Stem Cell Transplantation Institute at City of Hope in Duarte, Calif. Dr. Kwak will work with the director of the Institute, Stephen J. Forman, MD, to oversee recruitment, clinical and laboratory research, and faculty development.
Dr. Kwak is also director of the Toni Stephenson Lymphoma Center, vice president and deputy director of the comprehensive cancer center, and the Dr. Michael Friedman Professor in Translational Medicine. Dr. Kwak was named one of TIME magazine’s “100 Most Influential People,” received the Chang-Yul Oh Memorial Award from the Korean Medical Association, and won the Ho-Am Prize in Medicine.
Also at City of Hope, Tanya Siddiqi, MD, has been appointed director of the chronic lymphocytic leukemia (CLL) program within the Toni Stephenson Lymphoma Center of the Hematologic Malignancies and Stem Cell Transplantation Institute. In this role, Dr. Siddiqi will oversee research efforts related to CLL. This includes maintaining the CLL tissue bank she developed, conducting translational studies and clinical trials, and investigating novel therapies for CLL.
Dr. Siddiqi is also an associate clinical professor in the department of hematology & hematopoietic cell transplantation, is the supervising physician of City of Hope’s anticoagulation clinic, and works in the Gehr Family Center for Leukemia Research. Dr. Siddiqi is a member of the National Comprehensive Cancer Network panels for CLL/SLL/hairy cell leukemia and venous thromboembolism.
Lastly, James M. Martin, MD, has been appointed assistant professor in the hematology and bone marrow transplant program within the department of hematology/oncology at Fox Chase Cancer Center in Philadelphia.
Dr. Martin received a medical degree from Ohio State University, Columbus, and completed an internship and residency at Rhode Island Hospital/Brown University, in Providence. He joined Fox Chase Cancer Center/Temple University in 2016 for a 3-year fellowship.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
The University of Arizona (UA) Cancer Center has a new interim director, two hematologists have earned new positions at City of Hope, and an assistant professor has joined Fox Chase Cancer Center.
William Cance, MD, has been appointed interim director of the UA Cancer Center. In this role, he will oversee clinical operations and research at the center’s primary locations in Tucson and Phoenix. He will also lead the UA Cancer Center’s efforts to renew its 5-year Cancer Center Support Grant from the National Cancer Institute (NCI).
In addition to his new role, Dr. Cance is a professor at the UA Colleges of Medicine and Pharmacy in Phoenix. He is board certified in general surgery and specializes in thyroid cancer, parathyroid disease, sarcoma, and gastrointestinal cancer. Dr. Cance has received funding from NCI, has served on the NCI Board of Scientific Counselors, and is a member of NCI Subcommittee F.
In other news, Larry Kwak, MD, PhD, has been appointed the deputy director of the Hematologic Malignancies and Stem Cell Transplantation Institute at City of Hope in Duarte, Calif. Dr. Kwak will work with the director of the Institute, Stephen J. Forman, MD, to oversee recruitment, clinical and laboratory research, and faculty development.
Dr. Kwak is also director of the Toni Stephenson Lymphoma Center, vice president and deputy director of the comprehensive cancer center, and the Dr. Michael Friedman Professor in Translational Medicine. Dr. Kwak was named one of TIME magazine’s “100 Most Influential People,” received the Chang-Yul Oh Memorial Award from the Korean Medical Association, and won the Ho-Am Prize in Medicine.
Also at City of Hope, Tanya Siddiqi, MD, has been appointed director of the chronic lymphocytic leukemia (CLL) program within the Toni Stephenson Lymphoma Center of the Hematologic Malignancies and Stem Cell Transplantation Institute. In this role, Dr. Siddiqi will oversee research efforts related to CLL. This includes maintaining the CLL tissue bank she developed, conducting translational studies and clinical trials, and investigating novel therapies for CLL.
Dr. Siddiqi is also an associate clinical professor in the department of hematology & hematopoietic cell transplantation, is the supervising physician of City of Hope’s anticoagulation clinic, and works in the Gehr Family Center for Leukemia Research. Dr. Siddiqi is a member of the National Comprehensive Cancer Network panels for CLL/SLL/hairy cell leukemia and venous thromboembolism.
Lastly, James M. Martin, MD, has been appointed assistant professor in the hematology and bone marrow transplant program within the department of hematology/oncology at Fox Chase Cancer Center in Philadelphia.
Dr. Martin received a medical degree from Ohio State University, Columbus, and completed an internship and residency at Rhode Island Hospital/Brown University, in Providence. He joined Fox Chase Cancer Center/Temple University in 2016 for a 3-year fellowship.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
Hemostasis researcher passes away at age 72
George J. Broze Jr., MD, a former professor of medicine at Washington University School of Medicine in St. Louis, died following a heart attack on June 19, 2019, at the age of 72.
Dr. Broze was born in Seattle. He earned a bachelor’s degree from the University of Washington in Seattle and a medical degree from the University of Washington School of Medicine in St. Louis. Dr. Broze completed his internship and residency at North Carolina Memorial Hospital in Chapel Hill.
Dr. Broze became a clinical fellow in hematology at Washington University in 1976 and began teaching there in 1979. Dr. Broze practiced at the Jewish Hospital, Barnes Hospital, and Barnes-Jewish Hospital.
Dr. Broze’s research was focused on hemostasis and the relationship between coagulation and inflammation. He and his colleagues isolated and characterized tissue factor pathway inhibitor, uncovered a pathway for coagulation factor XI activation, and characterized the protein Z-dependent protease inhibitor serpinA10.
Dr. Broze is survived by his wife, two sons, and brother.
In happier news, Thomas J. Smith, MD, of the Johns Hopkins University School of Medicine in Baltimore, has won the Walther Cancer Foundation Palliative and Supportive Care in Oncology Endowed Award and Lecture from the American Society of Clinical Oncology.
The award is given to someone who “has made significant contributions to palliative care practice and research in oncology,” according to ASCO. Dr. Smith and his colleagues are known for their work showing that end-of-life palliative care can improve patient symptoms and quality of life while reducing the cost of care.
Dr. Smith will receive the award and deliver a keynote address at the 2019 Supportive Care in Oncology Symposium, which is set to take place Oct. 25-26 in San Francisco.
Meanwhile, Asya Nina Varshavsky-Yanovsky, MD, PhD, has joined Fox Chase Cancer Center in Philadelphia as an assistant professor in the hematology and bone marrow transplant programs within the department of hematology/oncology.
Dr. Varshavsky-Yanovsky earned her MD and PhD from the Technion-Israel Institute of Technology in Haifa, Israel. She joined Fox Chase Cancer Center/Temple University in 2016 for a 3-year fellowship in hematology/oncology.
Susmitha Apuri, MD, has joined Florida Cancer Specialists & Research Institute and is seeing patients in Inverness. She is board certified in medical oncology, hematology, and internal medicine.
Dr. Apuri earned her medical degree from NTR University of Health Sciences in Vijayawada, India; completed her internship and residency in internal medicine at the University of Miami Miller School of Medicine; and completed her fellowship in hematology/oncology at the University of South Florida/H. Lee Moffitt Cancer and Research Institute in Tampa. Her research and practice interests include malignant and nonmalignant hematology as well as breast, lung, and colorectal cancer.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
George J. Broze Jr., MD, a former professor of medicine at Washington University School of Medicine in St. Louis, died following a heart attack on June 19, 2019, at the age of 72.
Dr. Broze was born in Seattle. He earned a bachelor’s degree from the University of Washington in Seattle and a medical degree from the University of Washington School of Medicine in St. Louis. Dr. Broze completed his internship and residency at North Carolina Memorial Hospital in Chapel Hill.
Dr. Broze became a clinical fellow in hematology at Washington University in 1976 and began teaching there in 1979. Dr. Broze practiced at the Jewish Hospital, Barnes Hospital, and Barnes-Jewish Hospital.
Dr. Broze’s research was focused on hemostasis and the relationship between coagulation and inflammation. He and his colleagues isolated and characterized tissue factor pathway inhibitor, uncovered a pathway for coagulation factor XI activation, and characterized the protein Z-dependent protease inhibitor serpinA10.
Dr. Broze is survived by his wife, two sons, and brother.
In happier news, Thomas J. Smith, MD, of the Johns Hopkins University School of Medicine in Baltimore, has won the Walther Cancer Foundation Palliative and Supportive Care in Oncology Endowed Award and Lecture from the American Society of Clinical Oncology.
The award is given to someone who “has made significant contributions to palliative care practice and research in oncology,” according to ASCO. Dr. Smith and his colleagues are known for their work showing that end-of-life palliative care can improve patient symptoms and quality of life while reducing the cost of care.
Dr. Smith will receive the award and deliver a keynote address at the 2019 Supportive Care in Oncology Symposium, which is set to take place Oct. 25-26 in San Francisco.
Meanwhile, Asya Nina Varshavsky-Yanovsky, MD, PhD, has joined Fox Chase Cancer Center in Philadelphia as an assistant professor in the hematology and bone marrow transplant programs within the department of hematology/oncology.
Dr. Varshavsky-Yanovsky earned her MD and PhD from the Technion-Israel Institute of Technology in Haifa, Israel. She joined Fox Chase Cancer Center/Temple University in 2016 for a 3-year fellowship in hematology/oncology.
Susmitha Apuri, MD, has joined Florida Cancer Specialists & Research Institute and is seeing patients in Inverness. She is board certified in medical oncology, hematology, and internal medicine.
Dr. Apuri earned her medical degree from NTR University of Health Sciences in Vijayawada, India; completed her internship and residency in internal medicine at the University of Miami Miller School of Medicine; and completed her fellowship in hematology/oncology at the University of South Florida/H. Lee Moffitt Cancer and Research Institute in Tampa. Her research and practice interests include malignant and nonmalignant hematology as well as breast, lung, and colorectal cancer.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
George J. Broze Jr., MD, a former professor of medicine at Washington University School of Medicine in St. Louis, died following a heart attack on June 19, 2019, at the age of 72.
Dr. Broze was born in Seattle. He earned a bachelor’s degree from the University of Washington in Seattle and a medical degree from the University of Washington School of Medicine in St. Louis. Dr. Broze completed his internship and residency at North Carolina Memorial Hospital in Chapel Hill.
Dr. Broze became a clinical fellow in hematology at Washington University in 1976 and began teaching there in 1979. Dr. Broze practiced at the Jewish Hospital, Barnes Hospital, and Barnes-Jewish Hospital.
Dr. Broze’s research was focused on hemostasis and the relationship between coagulation and inflammation. He and his colleagues isolated and characterized tissue factor pathway inhibitor, uncovered a pathway for coagulation factor XI activation, and characterized the protein Z-dependent protease inhibitor serpinA10.
Dr. Broze is survived by his wife, two sons, and brother.
In happier news, Thomas J. Smith, MD, of the Johns Hopkins University School of Medicine in Baltimore, has won the Walther Cancer Foundation Palliative and Supportive Care in Oncology Endowed Award and Lecture from the American Society of Clinical Oncology.
The award is given to someone who “has made significant contributions to palliative care practice and research in oncology,” according to ASCO. Dr. Smith and his colleagues are known for their work showing that end-of-life palliative care can improve patient symptoms and quality of life while reducing the cost of care.
Dr. Smith will receive the award and deliver a keynote address at the 2019 Supportive Care in Oncology Symposium, which is set to take place Oct. 25-26 in San Francisco.
Meanwhile, Asya Nina Varshavsky-Yanovsky, MD, PhD, has joined Fox Chase Cancer Center in Philadelphia as an assistant professor in the hematology and bone marrow transplant programs within the department of hematology/oncology.
Dr. Varshavsky-Yanovsky earned her MD and PhD from the Technion-Israel Institute of Technology in Haifa, Israel. She joined Fox Chase Cancer Center/Temple University in 2016 for a 3-year fellowship in hematology/oncology.
Susmitha Apuri, MD, has joined Florida Cancer Specialists & Research Institute and is seeing patients in Inverness. She is board certified in medical oncology, hematology, and internal medicine.
Dr. Apuri earned her medical degree from NTR University of Health Sciences in Vijayawada, India; completed her internship and residency in internal medicine at the University of Miami Miller School of Medicine; and completed her fellowship in hematology/oncology at the University of South Florida/H. Lee Moffitt Cancer and Research Institute in Tampa. Her research and practice interests include malignant and nonmalignant hematology as well as breast, lung, and colorectal cancer.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
MOVERS IN MEDICINE
Stand Up To Cancer adds research muscle
Two researchers have joined Stand Up To Cancer’s scientific advisory committee, which directs the organization’s research initiatives, reviews grant proposals, and oversees active grants.
One new committee member is John D. Carpten, PhD, of the University of Southern California in Los Angeles. Dr. Carpten’s research encompasses several cancer types and focuses on the use of genomic technologies and bioinformatics analysis.
The other new committee member is Roderic I. Pettigrew, MD, PhD, of Texas A&M University in College Station. Dr. Pettigrew is known for pioneering four-dimensional imaging of the cardiovascular system using MRI.
In other news, Fox Chase Cancer Center in Philadelphia has appointed five new endowed chairs. The chair holders “will have new resources to strengthen [the center’s] efforts in various areas of cancer research and to implement more effective cancer treatments,” according to Fox Chase.
Hossein Borghaei, DO, now holds the Gloria and Edmund M. Dunn Chair in Thoracic Oncology. Dr. Borghaei conducts research focused on the development of new cancer treatments, particularly immunotherapies and monoclonal antibodies.
Margie L. Clapper, PhD, holds the Samuel M.V. Hamilton Chair in Cancer Prevention. Dr. Clapper is known for creating one of the first programs in the United States to focus on reducing the risk of cancer in high-risk patients and supporting the early detection and prevention of cancers.
Erica Golemis, PhD, holds the William Wikoff Smith Chair in Cancer Research. Dr. Golemis studies changes in cell signaling associated with tumor development and progression, as well as cancer treatment resistance.
Mariusz A. Wasik, MD, holds the Donald E. and Shirley C. Morel, Stanley and Stella Bayster Chair in Molecular Diagnostics. Dr. Wasik’s research is focused on aberrant cell signaling and oncogenic mutations in lymphomas, as well as cell transformation driven by ALK.
Johnathan R. Whetstine, PhD, holds the Jack Schultz Chair in Basic Science. Dr. Whetstine studies epigenetic mechanisms that regulate cell cycle progression, impact cancer therapy, and drive copy gain, amplifications, and drug resistance.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
Two researchers have joined Stand Up To Cancer’s scientific advisory committee, which directs the organization’s research initiatives, reviews grant proposals, and oversees active grants.
One new committee member is John D. Carpten, PhD, of the University of Southern California in Los Angeles. Dr. Carpten’s research encompasses several cancer types and focuses on the use of genomic technologies and bioinformatics analysis.
The other new committee member is Roderic I. Pettigrew, MD, PhD, of Texas A&M University in College Station. Dr. Pettigrew is known for pioneering four-dimensional imaging of the cardiovascular system using MRI.
In other news, Fox Chase Cancer Center in Philadelphia has appointed five new endowed chairs. The chair holders “will have new resources to strengthen [the center’s] efforts in various areas of cancer research and to implement more effective cancer treatments,” according to Fox Chase.
Hossein Borghaei, DO, now holds the Gloria and Edmund M. Dunn Chair in Thoracic Oncology. Dr. Borghaei conducts research focused on the development of new cancer treatments, particularly immunotherapies and monoclonal antibodies.
Margie L. Clapper, PhD, holds the Samuel M.V. Hamilton Chair in Cancer Prevention. Dr. Clapper is known for creating one of the first programs in the United States to focus on reducing the risk of cancer in high-risk patients and supporting the early detection and prevention of cancers.
Erica Golemis, PhD, holds the William Wikoff Smith Chair in Cancer Research. Dr. Golemis studies changes in cell signaling associated with tumor development and progression, as well as cancer treatment resistance.
Mariusz A. Wasik, MD, holds the Donald E. and Shirley C. Morel, Stanley and Stella Bayster Chair in Molecular Diagnostics. Dr. Wasik’s research is focused on aberrant cell signaling and oncogenic mutations in lymphomas, as well as cell transformation driven by ALK.
Johnathan R. Whetstine, PhD, holds the Jack Schultz Chair in Basic Science. Dr. Whetstine studies epigenetic mechanisms that regulate cell cycle progression, impact cancer therapy, and drive copy gain, amplifications, and drug resistance.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.
Two researchers have joined Stand Up To Cancer’s scientific advisory committee, which directs the organization’s research initiatives, reviews grant proposals, and oversees active grants.
One new committee member is John D. Carpten, PhD, of the University of Southern California in Los Angeles. Dr. Carpten’s research encompasses several cancer types and focuses on the use of genomic technologies and bioinformatics analysis.
The other new committee member is Roderic I. Pettigrew, MD, PhD, of Texas A&M University in College Station. Dr. Pettigrew is known for pioneering four-dimensional imaging of the cardiovascular system using MRI.
In other news, Fox Chase Cancer Center in Philadelphia has appointed five new endowed chairs. The chair holders “will have new resources to strengthen [the center’s] efforts in various areas of cancer research and to implement more effective cancer treatments,” according to Fox Chase.
Hossein Borghaei, DO, now holds the Gloria and Edmund M. Dunn Chair in Thoracic Oncology. Dr. Borghaei conducts research focused on the development of new cancer treatments, particularly immunotherapies and monoclonal antibodies.
Margie L. Clapper, PhD, holds the Samuel M.V. Hamilton Chair in Cancer Prevention. Dr. Clapper is known for creating one of the first programs in the United States to focus on reducing the risk of cancer in high-risk patients and supporting the early detection and prevention of cancers.
Erica Golemis, PhD, holds the William Wikoff Smith Chair in Cancer Research. Dr. Golemis studies changes in cell signaling associated with tumor development and progression, as well as cancer treatment resistance.
Mariusz A. Wasik, MD, holds the Donald E. and Shirley C. Morel, Stanley and Stella Bayster Chair in Molecular Diagnostics. Dr. Wasik’s research is focused on aberrant cell signaling and oncogenic mutations in lymphomas, as well as cell transformation driven by ALK.
Johnathan R. Whetstine, PhD, holds the Jack Schultz Chair in Basic Science. Dr. Whetstine studies epigenetic mechanisms that regulate cell cycle progression, impact cancer therapy, and drive copy gain, amplifications, and drug resistance.
Movers in Medicine highlights career moves and personal achievements by hematologists and oncologists. Did you switch jobs, take on a new role, climb a mountain? Tell us all about it at hematologynews@mdedge.com, and you could be featured in Movers in Medicine.